dc.contributor.author | Baltabekova, A. Zh. | |
dc.contributor.author | Shagyrova, Zh. S. | |
dc.contributor.author | Voykov, M. | |
dc.contributor.author | Ramanculov, E. M. | |
dc.contributor.author | Shustov, A. V. | |
dc.date.accessioned | 2015-10-22T11:53:03Z | |
dc.date.available | 2015-10-22T11:53:03Z | |
dc.date.issued | 2014 | |
dc.identifier.uri | http://nur.nu.edu.kz/handle/123456789/424 | |
dc.description.abstract | Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. | ru_RU |
dc.language.iso | en | ru_RU |
dc.publisher | Nazarbayev University | ru_RU |
dc.subject | immunoglobulin E | ru_RU |
dc.subject | human IgE | ru_RU |
dc.subject | immunodominant region | ru_RU |
dc.subject | split core technology | ru_RU |
dc.title | Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE | ru_RU |
dc.type | Abstract | ru_RU |